Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | CTRC | Q99895 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036603 | 0.95 | CA1 (0.43) | CA1CA9CYP1A2TSHR | |
| SCHEMBL8755163 | 0.95 | CA1 (0.43) | CA1CA9CYP1A2TSHR | |
| SCHEMBL113746 | 0.95 | CA1 (0.43) | CA1CA9CYP1A2TSHR | |
| SCHEMBL8755171 | 0.95 | CA1 (0.43) | CA1CA9CYP1A2TSHR | |
| SCHEMBL11173078 | 0.88 | CA1 (0.44) | CA1CA9CYP1A2TSHR | |
| SCHEMBL28730837 | 0.88 | CA1 (0.44) | CA1CA9CYP1A2TSHR | |
| SCHEMBL13304668 | 0.86 | CA1 (0.38) | CA1CA9TSHR | |
| SCHEMBL28730832 | 0.86 | CA1 (0.43) | CA1CA9CYP1A2TSHR | |
| SCHEMBL7909099 | 0.86 | CA1 (0.43) | CA1CA9CYP1A2TSHR | |
| SCHEMBL3138434 | 0.84 | CA1 (0.37) | CA1CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100210635-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210635-A1 | RENIN INHIBITORS | REN, ACE, AGT | CA1 1185/4885CA9 243/4885CYP1A2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.